| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 9.1 | 9.7 |
| Profit before tax | -31.5 | -56.9 |
| Net income | -31.5 | -56.9 |
| EPS (diluted, $ a share) | $-1.90 | $-6.66 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -6.1% |
|---|---|
| Operating margin | -241.3% |
10-Q filed with the SEC, NASDAQ: STRO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Sutro Biopharma, Inc.: key numbers
- Share price
- $9.32Close, Nov 16
- Market cap
- $155M
- Shares outstanding
- 16.6MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Sutro Biopharma, Inc.
All →Sutro Biopharma Financial Results
Sutro Biopharma reported third quarter 2026 financial results, highlighting a cash position of $142.2 million which is expected to fund operations into the first half of 2028. The company advanced its clinical pipeline with the first patient dosed in the STRO-006 Phase 1 study and reported progress on its STRO-004 and STRO-227 ADC programs.
- Term
- 3 months
“Over the past year, we have delivered on our commitment to advance our next-generation ADCs with two programs, STRO-004 and STRO-006, entering the clinic in less than a year, and our dual-payload ADC, STRO-227, expected to follow in early 2027.”
Jane Chung, Chief Executive Officer of Sutro
“Early data from STRO-004 give us confidence in its potential to deliver meaningful clinical benefit with our proprietary ADC platform. In addition, our collaboration partner Astellas has initiated patient dosing with a second dual-payload immunostimulatory ADC, further highlighting our strong execution and ability to deliver differentiated, novel dual-payload ADCs.”
Jane Chung, Chief Executive Officer of Sutro